​

Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALGS Stock Forecast

Aligos Therapeutics (ALGS) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a -35.90% decline from the last price of $4.68.

- $8 $16 $24 $32 $40 High: $3 Avg: $3 Low: $3 Last Closed Price: $4.68

ALGS Stock Rating

Aligos Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

ALGS Price Target Upside V Benchmarks

TypeNameUpside
StockAligos Therapeutics-35.90%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.68$4.68$4.68
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2521---3
Mar, 2521---3
Feb, 2521---3
Jan, 2521---3
Dec, 2421---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2023Piper Sandler$3.00$1.22145.90%-35.90%
Jan 06, 2023Jefferies$3.00$0.99203.03%-35.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 20, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2024Piper SandlerOverweightOverweighthold
Aug 19, 2024H.C. WainwrightBuyinitialise
Jul 19, 2024Piper SandlerOverweightOverweighthold
May 17, 2024Piper SandlerOverweightOverweighthold
Jan 06, 2023BarclaysEqual-Weightdowngrade
Jan 06, 2023Piper SandlerOverweightupgrade
Nov 03, 2022SVB LeerinkMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.22$-2.25$-3.52$-20.94----
Avg Forecast$-78.73$-53.13$-34.25$-10.09$-11.92$-13.14$-15.68$-5.53
High Forecast$-61.97$-49.31$-30.93$-8.97$-8.13$-6.82$-7.57$-5.53
Low Forecast$-108.73$-60.76$-37.57$-11.21$-17.88$-19.46$-23.79$-5.53
Surprise %-95.91%-95.77%-89.72%107.53%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.36M$13.91M$15.53M-----
Avg Forecast$4.00M$12.55M$14.40M$3.73M$1.33M$32.50M$122.00M$239.01M
High Forecast$5.17M$13.94M$15.97M$4.58M$1.33M$32.50M$122.00M$239.01M
Low Forecast$3.34M$11.86M$12.82M$3.31M$1.33M$32.50M$122.00M$239.01M
Surprise %9.02%10.81%7.84%-----

Net Income Forecast

$-7B $-6B $-4B $-3B $-1B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-128.33M$-96.05M$-87.68M$-131.21M----
Avg Forecast$-5.06B$-1.32B$-851.92M$-251.06M$-323.39M$-326.84M$-390.02M$-137.55M
High Forecast$-3.98B$-1.23B$-769.31M$-223.19M$-202.17M$-169.64M$-188.29M$-137.55M
Low Forecast$-6.99B$-1.51B$-934.53M$-278.92M$-444.61M$-484.04M$-591.74M$-137.55M
Surprise %-97.46%-92.73%-89.71%-47.74%----

ALGS Forecast FAQ

Is Aligos Therapeutics stock a buy?

Aligos Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aligos Therapeutics is a favorable investment for most analysts.

What is Aligos Therapeutics's price target?

Aligos Therapeutics's price target, set by 5 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential -35.90% change from the previous closing price of $4.68.

How does Aligos Therapeutics stock forecast compare to its benchmarks?

Aligos Therapeutics's stock forecast shows a -35.90% downside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Aligos Therapeutics over the past three months?

  • April 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aligos Therapeutics’s EPS forecast?

Aligos Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-11.92, marking a -43.08% decrease from the reported $-20.94 in 2024. Estimates for the following years are $-13.14 in 2026, $-15.68 in 2027, and $-5.53 in 2028.

What is Aligos Therapeutics’s revenue forecast?

Aligos Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.33M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $32.5M, followed by $122M for 2027, and $239.01M for 2028.

What is Aligos Therapeutics’s net income forecast?

Aligos Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-323M, representing an 146.47% increase from the reported $-131M in 2024. Projections indicate $-327M in 2026, $-390M in 2027, and $-138M in 2028.